← All trials
NCT04398680
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 30, 2020
- Primary completion
- Dec 3, 2024
- Completion date
- Dec 3, 2024
- First posted
- May 22, 2020
- Last posted
- May 22, 2020
- Enrollment
- 40
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- GlaxoSmithKlineLead sponsor
- GlaxoSmithKlineStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.